In a double-blind, controlled cross-over trial, the effect of the mucolytic drug bromhexine (24 mg or 48 mg daily) was compared with a placebo over a period of 14 weeks in 21 severe chronic bronchitics (mean FEVI.0 0-8 1.). Each of the three treatment regimes was continued for four weeks with intervening single weeks on placebo tablets. As the subjects were outpatients, sodium fluorescein incorporated in the tablets was used as a drug marker. Satisfactory data were obtained in 18 patients. There was no significant improvement in clinical condition or ventilatory capacity nor change in sputum properties throughout the period of study. No side effects or significant change in blood values were detected.
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Bromhexine is a benzylamine derivative of vasicine, an alkaloid derived from the plant Adhatoda vasica, which is indigenous to the continent of Asia. It has been shown to reduce the viscosity of bronchial secretions in animals (Engelhorn and Piischmann, 1963) and man (Hamilton, Palmer, and Gent, 1970) probably by depolymerization of high molecular weight mucopolysaccharide fibres (Boyd and Sheppard, 1966) . Reduction of sputum viscosity should facilitate bronchial clearance in patients with diseases such as chronic bronchitis in which sputum may be copious, viscid, and difficult to expectorate. Since bromhexine is taken orally, its distribution and site of action within the lung should be uniform, thereby avoiding one of the major problems encountered in administering mucolytic agents by aerosol.
Previous studies of this drug in chronic bronchitis have not shown consistent results. Gent, Knowlson, and Prime (1969) found improvement lPresent address: Brompton Hospital, London S.W.3 in the clinical condition and ventilatory capacity of their patients, while others (Hamilton et al., 1970; Langlands, 1970) regime (i.e., weeks 0, 4, 5, 9, 10, and 14) .
Blood was taken weekly for haemoglobin, white cell count and differential, serum albumin, globulin, bilirubin, and enzymes (aspartate aminotransferase, 5 nucleotidase, and alkaline phosphatase). Urine was tested for fluorescence.
Full weather details, including ambient temperature, barometric pressure and humidity, were obtained weekly from the local meteorological station to determine any correlation between change in weather conditions and clinical status. This seemed relevant since the trial was conducted in the winter and spring months.
RESULTS
All but three patients completed the trial satisfactorily, leaving 18 for analysis. Three patients had a single exacerbation of chronic bronchitis which settled within 10 to 14 days. These exacerbations were equally spaced throughout the trial and were not related to any particular regime. The detection of urinary fluorescence confirmed that every patient had taken his tablets.
Analysis of the data showed no uniform significant changes, either in symptoms, signs, sputum or pulmonary function, during the trial period (Tables  II and Ill) . There were no trends corresponding to the prevailing weather conditions. There were no side effects from bromhexine therapy and no significant alteration in the blood count, serum enzymes, serum proteins or bilirubin.
FOLLOW-UP The patients were assessed again two years later, when they were asked specifically for comments on their progress during the clinical trial. At this time two patients had died and one could not be traced, leaving 15 who were interviewed. Six patients thought they were improved generally during the trial, three thought their respiratory symptoms were reduced, and seven noted no change. Of the three patients who noted respiratory improvement, all thought their sputum was thinner and more easily cleared. These comments must be viewed in the light of the time that had elapsed since the trial, the failure of the cross-over to show significant benefit from the active drug, and the tendency of patients in clinical trials to show symptomatic improvement. This last point was demonstrated by a trend towards improvement during the trial, irrespective of the treatment order. Comparison of the ventilatory tests in 1969 and the present showed the expected deterioration.
DISCUSSION
The results of the present double-blind crossover trial of bromhexine in doses of 24 mg or 48 mg daily in patients with chronic bronchitis show no significant effects of the drug on symptoms, signs or pulmonary function. These patients had severe airways obstruction as evaluated by a mean FEV1.0 of 0-8 1. In a group of 13 bronchitics of similar severity (mean FEV1.0 0-7 1.), treated with bromhexine, 24 mg daily for 14 days in hospital, Langlands (1970) also found no drug effect, and Hamilton et al. (1970) , treating a further group of 12 severe bronchitics (mean FEVi-o 28-8% predicted) with 48 mg daily for 11 days, also found no improvement in ventilatory capacity or overall respiratory state. In contrast, Gent et al. (1969) found significant improvement in their mixed group of 23 patients treated with bromhexine, 24 mg daily for one week; this improvement was seen only in the winter months, and the patients were much less severely disabled than those in the present study, those with chronic bronchitis or asthma having a mean FEVio of 2-4 1. Christensen et al. (1971) , in a long-term study over two winters, noted clinical improvement principally in moderate bronchitics (mean FEV1.0 1-45 1.) but not in those with severe disease (mean FEV1., 0-9 1.). Thus the results of the present study agree with these previous findings in severe bronchitics and suggest that patients with FEVi o of less than 1-0 1. are unlikely to be improved by bromhexine. In these patients it is probable that the effects of irreversible structural change within the bronchi and lung parenchyma greatly exceed those of sputum in the airways. Although sputum may increase airway resistance (Clarke, Jones, and Oliver, 1970) , its effect on the overall ventilatory capacity of bronchitics is largely unknown.
Examination of the sputum data showed the expected variation between patients but also differences for the same patient over the period of study. This may reflect the difficulties of collecting and measuring sputum encountered by the average bronchitic at home. The volume of sputum will depend on the efficiency of the cough mechanism in clearing the bronchial tree as well as the addition of saliva. Severe bronchitics, whose airways are abnormally collapsible, have an inefficient cough mechanism (Langlands, 1967) so that expectorated sputum may not closely reflect sputum production. In these patients the inefficiency of their cough mechanism is likely to be the major factor determining bronchial clearance, rather than the viscosity of sputum. Furthermore, as sputum is probably thixotropic, the physical agitation of expectoration will alter its viscosity, as will any delay in carrying out the measurement of pouring time (Sturgess, Palfrey, and Reid, 1970) . These factors could account for the variation in viscosity measurements.
In clinical trials on outpatients, confirmation that the drug is being taken is important and previous methods have proved unreliable. The methlod of incorporating a small amount of sodium fluorescein into the tablets has recently been described by Thompson and Stowers (1971) who found fluorescein to be a satisfactory drug marker. This provided a simple, innocuous but effective way of checking whether the patient was taking his tablets by the detection of urinary fluorescence.
While the results of this trial show no benefit from bromhexine in severe bronchitics, previous trials suggest that patients at a less advanced stage are improved. If bromhexine enhances bronchial clearance in these less advanced cases, the inevitable clinical deterioration of the chronic bronchitic may be slowed or arrested. This last point still awaits further clinical proof. 
